These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 12853839)
21. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Hatta Y; Takeuchi S; Yokota J; Koeffler HP Br J Cancer; 1997; 75(9):1256-62. PubMed ID: 9155043 [TBL] [Abstract][Full Text] [Related]
22. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057 [TBL] [Abstract][Full Text] [Related]
23. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Dahia PL; Aguiar RC; Honegger J; Fahlbush R; Jordan S; Lowe DG; Lu X; Clayton RN; Besser GM; Grossman AB Oncogene; 1998 Jan; 16(1):69-76. PubMed ID: 9467944 [TBL] [Abstract][Full Text] [Related]
24. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Pollock PM; Welch J; Hayward NK Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846 [TBL] [Abstract][Full Text] [Related]
25. Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies. Nakatsuka S; Liu A; Yao M; Takakuwa T; Tomita Y; Hoshida Y; Nishiu M; Aozasa K Int J Oncol; 2003 Mar; 22(3):561-8. PubMed ID: 12579309 [TBL] [Abstract][Full Text] [Related]
26. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Rosner M; Freilinger A; Hengstschläger M Mutat Res; 2006 Sep; 613(1):10-6. PubMed ID: 16713332 [TBL] [Abstract][Full Text] [Related]
27. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells. Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687 [TBL] [Abstract][Full Text] [Related]
29. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112 [TBL] [Abstract][Full Text] [Related]
30. Mutation and polymorphism analysis in the tuberous sclerosis 2 (TSC2) gene. Gilbert JR; Guy V; Kumar A; Wolpert C; Kandt R; Aylesworth A; Roses AD; Pericak-Vance MA Neurogenetics; 1998 Aug; 1(4):267-72. PubMed ID: 10732801 [TBL] [Abstract][Full Text] [Related]
31. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Habuchi T; Luscombe M; Elder PA; Knowles MA Genomics; 1998 Mar; 48(3):277-88. PubMed ID: 9545632 [TBL] [Abstract][Full Text] [Related]
32. Mutation screening of the entire coding regions of the TSC1 and the TSC2 gene with the protein truncation test (PTT) identifies frequent splicing defects. Mayer K; Ballhausen W; Rott HD Hum Mutat; 1999; 14(5):401-11. PubMed ID: 10533066 [TBL] [Abstract][Full Text] [Related]
34. The TSC1 gene product, hamartin, negatively regulates cell proliferation. Miloloza A; Rosner M; Nellist M; Halley D; Bernaschek G; Hengstschläger M Hum Mol Genet; 2000 Jul; 9(12):1721-7. PubMed ID: 10915759 [TBL] [Abstract][Full Text] [Related]
35. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Pymar LS; Platt FM; Askham JM; Morrison EE; Knowles MA Hum Mol Genet; 2008 Jul; 17(13):2006-17. PubMed ID: 18397877 [TBL] [Abstract][Full Text] [Related]
36. Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Eydmann ME; Knowles MA Cancer Genet Cytogenet; 1997 Feb; 93(2):167-71. PubMed ID: 9078303 [TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Kawamata N; Morosetti R; Miller CW; Park D; Spirin KS; Nakamaki T; Takeuchi S; Hatta Y; Simpson J; Wilcyznski S Cancer Res; 1995 Jun; 55(11):2266-9. PubMed ID: 7757974 [TBL] [Abstract][Full Text] [Related]
38. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Friedrich MG; Riethdorf S; Erbersdobler A; Tiemer C; Schwaibold H; Sölter JK; Huland E; Riethdorf L; Conrad S; Hammerer PG; Huland H Eur Urol; 2001 Feb; 39(2):159-66. PubMed ID: 11223675 [TBL] [Abstract][Full Text] [Related]
39. Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer. Shin JY; Kim HS; Lee KS; Kim J; Park JB; Won MH; Chae SW; Choi YH; Choi KC; Park YE; Lee JY Exp Mol Med; 2000 Jun; 32(2):79-83. PubMed ID: 10926119 [TBL] [Abstract][Full Text] [Related]
40. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]